The company announced that its has been granted for product patents each from Eurasia, Europe, Israel and Macau corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2030.
| Subscribe To Our Free Newsletter |
